Coherus BioSciences

Attending #TEXPERS2024 Summer Educational Forum? This afternoon, Coherus CEO Denny Lanfear will share his insights on the small-cap biotech sector.

Attending CHI's IO Summit? Don't miss our presentation on casdozokitug, our anti-IL-27 antibody. IL-27, a heterodimeric cytokine expressed by macrophages and myeloid cells, regulates the intensity and duration of immune responses in several pathological conditions, including cancer. Upregulation of IL-27 promotes tumor growth and progression in preclinical models, and is implicated in resistance to PD-1 inhibitors. Casdozokitug is a potent and selective anti-IL-27 antibody that has demonstrated immune activation and single-agent tumor response in Phase 1 clinical trials. #IOSUMMIT

We are excited to announce the appointment of Bryan McMichael as Chief Financial Officer of Coherus. Bryan brings deep financial expertise to Coherus honed throughout his time at Gilead Sciences and further demonstrated since he joined Coherus in 2021. Read more about Bryan here: https://bit.ly/4clb7Me

Join us for our Q2 2024 earnings call today, starting at 5:00 pm ET, to hear about our Q2 financial results and recent business highlights. Press release: https://bit.ly/4cigjAk Listen to the webcast: https://bit.ly/46yRSgL

Coherus will report Q2 2024 financial results on August 8, 2024. Starting at 5 pm EDT, CEO Denny Lanfear and the executive team will host a conference call and webcast to discuss Q2 2024 financial results and recent business highlights. Webcast link https://bit.ly/46yRSgL

Aligning with our strategic focus on oncology, today we announced the divestiture of YUSIMRY in a $40 million upfront all-cash transaction. Meitheal Pharmaceuticals, Inc. will continue to commercialize YUSIMRY in the U.S. Read the press release here: https://bit.ly/3XFG4qy

Congratulations to our partner, Shanghai Junshi Biosciences Co Ltd / TopAlliance Biosciences Inc, for the NMPA approval of toripalimab as a first-line treatment for patients with advanced triple-negative breast cancer in China. In the U.S., we are advancing the development of toripalimab in combination with our novel I-O pipeline and through clinical collaborations such as INOVIO Pharmaceuticals, Inc. and Cancer Research Institute (CRI)

: Don’t miss today’s 2024 Jefferies Global Healthcare Conference presentation. Coherus CEO Denny Lafear will present a company update this morning at 8:30 am ET. Listen to the webcast: https://bit.ly/4aFMVmL #JefferiesHealthcare

We are excited to announce that Rita Karachun CPA, CGMA, has joined Coherus’ Board of Directors. Rita brings extensive financial, operational, and strategic transformational expertise to our Board of Directors. Read more about the background of this exceptional leader: https://bit.ly/3V9yi5x #biotech #leadership 

Meet with me at #BIO2024! Reach out and connect with Coherus’ Business Development team, Scott Saywell and Christopher Franco at BIO.